Shots:
- The P-III study involves assessing JTA-004 (enhanced viscosupplement) vs PBO and the active comparator to reduce pain measured by the WOMAC pain subscale in patients with osteoarthritic pain in the knee
- The study showed that all treatment arms have similar efficacy, no significant difference in knee pain reduction b/w JTA-004, PBO, and active comparator @3mos. after treatment. JTA-004 have a favorable safety profile like PBO and comparator
- The company is focusing on the development of its core assets, the allogeneic cell therapy platform, including ALLOB, which is currently being evaluated in a P-IIb study in 178 patients with fresh tibial fractures at risk of delayed or non-union
Click here to read full press release/ article | Ref: Globe Newswire | Image: Ortho Spine News
The post Bone Therapeutics’s JTA-004 Fails to Meet its All Endpoints in P-III Study for Knee Osteoarthritis first appeared on PharmaShots.
